Interim Term Financial Results Ended September 2013

November 6, 2013 KYORIN Holdings, Inc. President Masahiro Yamashita





■Outline of Consolidated Financial Results for the Interim Term Ended September 2013

Trends of mainstay products and Status of generic drugs

■Status of development pipeline

■Environmental Hygiene business

■Consolidated Financial Results Forecast for the Year Ending March 31 2014 and Dividends



Outline of Consolidated Financial Results for the Interim Term Ended September 2013



	Sep/12	Sep/13	Change (actual)	% Y/Y	Change (forecast)
Net Sales	480	509	+ 29	+ 6.0	- 6
Operating Income	63	62	- 1	- 0.9	- 5
Ordinary Income	66	65	- 1	- 1.2	- 5
Net Income	43	44	+ 1	+ 2.4	- 2



4

(unit: ¥100mil) Change Change % Y/Y Sep/13 **Sep/12** (actual) (forecast) **Net Sales** 480 509 + 29 +6.0- 6 470 500 + 30 +6.4- 8 397 429 + 32 + 8.0- 6 Sales of new Ethical 387 417 + 7.9 + 30 Japan - 6 ethical drugs drugs 10 12 +2 + 13.5+ 1 business **Overseas** 51 **Generic drugs** 52 + 2.5 + 1 + 1 **Over-the-counter** 23 20 - 3 - 12.9 - 2 drugs 9 **Healthcare Business** 8 - 11.9 - 1 + 1

	Explanation of Variances
new ethical drugs(Japan)	 •influence of KYORIN Pharmaceutical Facilities sales (6 months) •increase of main product (Kipres, Pentasa etc.). Fall below forecast(mainly Kipres) •increase of royalty (licensing out product)
new ethical drugs(overseas)	sales of Gatifloxacin increased effect of exchange rate (sales of Allergan: FY12 2Q \$44MM→FY13 2Q \$35MM)
Generic drugs	increase of health insurance pharmacy market's sales
Over-the-counter drugs	otc and sales others decreased
Healthcare Business	sales decreased because of concentration of distribution route to mail order system




		Sep/12	Sep/13	Change (actual)	% Y/Y	Change (forecast)
Net S	Sales	480	509	+ 29	+ 6.0	- 6
Cost	of Sales	181	191	+ 10	+ 5.5	-
SG&	A	236	255	+ 19	+ 8.3	-
	R&D expenses	49	61	+ 12	+ 25.1	+ 4
	SG&A expenses	187	194	+ 7	+ 3.9	-
Оре	rating Income	63	62	- 1	- 0.9	- 5
Ordi	nary Income	66	65	- 1	- 1.2	- 5
Net I	ncome	43	44	+ 1	+ 2.4	- 2

	Explanation of Variances
Onereting	 >gross profit Increased ¥1.9bln(increase of sales , cost of sales ratio remained almost the same y/y). Fall below forecast(mainly Kipres)
Operating Income	> <u>R&D expenses</u> •progress of the pipeline(KRP-209 Ph2a) (y/y +¥1.2bln、forecast + ¥0.4bln)
	 SG&A Expenses (excluding R&D Expenses) Increased + 0.7bln , Fall below forecast (reduction of cost)

Highlights of Business Performance



(Units: ¥100mil)



<u>Highlight</u>

Net Sales increased ¥2.9billion year

on year

 increase of Japan new ethical drugs sales

 effect of KYORIN pharmaceutical Facilities sales

<u>Highlight</u>

Cost of Sales ratio remained almost the same level as the previous year.

Gross Profit increased ¥1.9billion year on year

<u>Highlight</u>

SG&A expenses increased ¥1.9billion year on year.

 R&D expenses increased ¥1.2billion (progress of the pipeline)
 SG&A(excluding R&D) increased ¥0.7billion

Operating Income decreased ¥0.1 billion year on year.



	Sep/12	Sep/13	Change (actual)	% Y/Y	Change (forecast)
Kipres	163	171	+ 8	+ 5.0	- 6
Mucodyne	83	82	- 1	- 0.6	+2
Pentasa	90	94	+ 4	+ 4.8	+ 1
Uritos	36	37	+ 1	+ 2.8	- 2
Gatifloxacin (Over seas)	9	10	+ 1	+ 14.1	+ 1

[For reference] Year on year rate of sales for medical institution (calculated based on drug price)


Kipres + 8.5%

(copyright 2013 IMS JAPAN K.K., Source : IMS - JPM Unauthorized copying prohibited)




Trends of mainstay products and Status of generic drugs



























Status of development pipeline

Drug Development Pipeline: Progress in FY2013





progress in FY13 first half

schedule of FY13 second half


Kyorin

Flutiform : a combination drug for asthma




>Approved on September 2013 (the drug price in Japan is due to list on November) In oversea markets : launched in 12 European countries by Mundi pharma.

> [Asthma Prevention and Management Guideline 2012, Japan] (Japanese Society of Allergology)



Even if it has taken controller, 60 to 80% of the patients (treatment steps2~4) are Partly Controlled



About Partly Controlled (One or more features of Following items)

- Nocturnal/Daytime symptoms : More than once/week
- •Need for reliever/ rescue treatment : More than once/week
- •Limitations of activities : Any
- •Lung function (PEF or FEV₁) : < 80% predicted or personal best (if known) •circadian change of PEF : < 20%
- •Exacerbations : One or more/year

Flutiform : a combination drug for asthma



LABA: a substance that rapidly dilates the bronchi

formoterol

fumarate

Flutiform

ICS:a substance that

exerts a potent antiinflammatory effect fluticasone

propionate

About Flutiform :

- **1.** Materializes ideal combination of potent ICS and rapid, long-lasting LABA. (Best Combination)
- 2. offers convenience and better compliance of the patients.

3. easy to use : MDI device offers several advantages such as reproducible doses per actuation and suitability to patients with lowered respiratory effort.

>Enlightenment of proper inhalation technique:

- 1. Provide inhalation guidance thoroughly (doctor, pharmacist, health-care provider)
- 2. enrich Informed consent tool

Understanding of product profile / Appropriate inhalation Realize the effect

Aim for early spread in the market



KRP-EPA605 (for the treatment of overactive bladder)

- ·prostaglandin EP1 receptor antagonist
- · different mechanism of action from existing therapies(β3 agonists and anticholinergic drugs)

■Status of Development

- Phase I (Oct. 2013)
- ·Co-development with KISSEI PHAMRACEUTICAL



aim to early approval of this drug

about new Development Research Laboratories Kyorin 🔾



location : 1848, Nogi, Nogi-machi, Shimotsuga-gun, Tochigi commencement of construction : Jan / 2014 completion of construction : Aug / 2015 commence operations : Oct / 2015



Environmental Hygiene business

Environmental Hygiene business

existing product : preserve and expand Disinfectant [Milton]

FY10

19

new product : promote spread of Multi-purpose disinfectant cleaner RUBYSTA

FY11

19

Aim at expanding use through introduction and standardization at hospitals while focusing on Category-1 facilities eligible for NHI points for measures against infections.

(forecast of FY13 : ¥0.3bln)

FY08

18

sales

(Note) Category-1 facilities eligible for NHI points for measures against infections: Those facilities that satisfy the requirements, such as the appointment of a full-time HAI manager and the setup of a department involved in the prevention of infections.

expand product lineup

kit product for helping prevent infection

FY09

19

•kit product for helping prevent from pandemic infection such as new strain of influenza etc.

([↑]Dupont[™] Tyvek_® protective suit is manufactured by Dupont USA)

•launch : Jul / 2013

Medical institutions, as designated public corporations, shall prepare a manual for medical care continuation and also stockpile protective kits and other items individually according to the MHLW guidelines.

kit product of Multi-purpose disinfectant cleaner RUBYSTA1 for vomit

reduce a risk of infection(norovirus) from vomit and to cleanup
 preparing for launch

(unit : ¥100mil)

FY13

(forecast)

20

FY12

20











Consolidated Financial Results Forecast for the Year Ending March 31 2014 and Dividends

Consolidated Financial Results Forecast for the Year Ending March 31, 2014



		Mar/13	Mar/14 Revised forecast	Change	% Change	Change from original forecast
		1,070	1,126	+ 56	+ 5.2	- 4
Net Sales	Ethical drugs business	1,052	1,109	+ 57	+ 5.5	- 4
	Healthcare(skincare) Business	19	17	- 2	- 9.0	0
Operating In	ncome	179	182	+ 3	+ 1.4	- 4
Ordinary Income		187	188	+ 1	+ 0.7	- 4
Net Income		124	124	0	- 0.2	- 3

	change (y/y) change (forecast) Explanation of Variances + 56 - 4			Explanation of Variances	Kyorin group will try to improve new records for
			sales and earnings		
	new ethical drugs (Japan) +45 -7 • influence of KYORIN Pharmaceutical Facilities sales •increase of main product (Kipres, Pentasa etc.) . Fall below forecast(mainly Kipres) •increase of royalty (licensing out product)		[for reference]		
sales (Overseas) Generic drugs	new ethical drugs (Overseas)	- 1	+ 2	Expenses associated with the income due to transfer of Pekiron assets were posted in the previous year.	•Cost of sales ratio : a slight increase year on year •SG&A ratio(include R&D expense) :
	Generic drugs	+ 13	+ 3	sales increased at KYORIN Rimedio	remain mostly level year on year •R&D expense ¥11.8bln(+0.7bln)
	Over-the-counter drugs	- 1	- 3	otc and sales others decreased	
Skin care business		- 2	0	sales decreased because of concentration of distribution route to mail order system	
Operating Income + 3 - 4		- 4	 <u>gross profit</u> increase year on year, effect of sales increase decreased against original forecast, influence of downward sales and rise of cost of sales ratio(mainly new product and exchange rate) <u>SG&A Expenses (excluding R&D Expenses)</u> Increase year on year(R&D,SG&A) Fall below original forecast (reduced R&D expense ¥ - 0.3bln) 	23	

Forecast of Mainstay Product Sales and Generic Drugs Kyorin



	Mar/13	Mar/14 Revised forecast	Change	% Change	Change from original forecast
Kipres	396	403	+7	+ 1.8	- 5
Mucodyne	191	188	- 3	- 1.6	+ 1
Pentasa	176	185	+ 9	+ 5.1	- 1
Uritos	75	80	+ 5	+ 7.2	- 4
Gatifloxacin (Over seas)	16	18	+2	+ 11.8	+2
Generic Drugs	101	114	+ 13	+ 13.3	+ 3



Basic Policy

The Company seeks to enhance its management base by balancing investments for growth and business continuity with shareholder returns. To this end, the Company aims for a consolidated payout ratio to shareholders of 30%.

Net Income

	FY12	FY13 (original forecast)	FY13 (revised forecast)
Net Income	¥12.4bln	¥12.7bln	¥12.4bln

Dividends

	FY12	FY13 (original forecast)	FY13 (revised forecast)
Dividend per share (Yen)	¥50.00 (interim ¥10.00)	¥52.00 (interim ¥10.00)	¥52.00 (interim ¥10.00)
Consolidated payout ratio(%)	30.1%	30.6%	31.2%



These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance.

Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.